United Therapeutics Corporation $UTHR Shares Bought by Comerica Bank

Key Points

• Comerica Bank increased its stake in United Therapeutics by 2.4% to 161,683 shares (about $78.8M), and institutional investors now own roughly 94.08% of the company.
• United Therapeutics beat EPS expectations ($7.70 vs. $6.78) but missed revenue estimates ($790.2M vs. $814.8M); the stock trades in a 12‑month range of $272.12–$607.89 with a market cap around $24.9B.
• Insiders have been net sellers, offloading 420,705 shares (~$226.3M) in the past three months, while analysts rate the stock a "Moderate Buy" with an average target of $601.50.

Comerica Bank boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 2.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 161,683 shares of the biotechnology company's stock after buying an additional 3,731 shares during the period. Comerica Bank owned 0.38% of United Therapeutics worth $78,780,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in UTHR. WealthCollab LLC increased its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares during the period. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares during the period. Abich Financial Wealth Management LLC acquired a new position in shares of United Therapeutics in the third quarter valued at approximately $44,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $567.16 on Monday. The firm has a market cap of $24.86 billion, a P/E ratio of 20.33, a PEG ratio of 1.61 and a beta of 0.75. The stock's 50 day simple moving average is $536.51 and its 200-day simple moving average is $494.61. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period in the previous year, the business earned $6.19 earnings per share. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 9,636 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,801,035.96. The trade was a 33.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $576.82, for a total value of $4,787,606.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $26,056,113.04. This trade represents a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 420,705 shares of company stock valued at $226,250,141 in the last three months. 10.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. Morgan Stanley boosted their target price on United Therapeutics from $471.00 to $519.00 and gave the company an "equal weight" rating in a report on Friday, April 10th. Royal Bank Of Canada boosted their target price on United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $601.50.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.